China’s top drug regulator has launched a one-year pilot program that will halve the current standard review time for investigational new drug (IND) applications for innovative drugs to 30 working days from the date the application is accepted.
Key Takeaways
-
China's one-year pilot program for innovative drugs’ IND applications will reduce the review time to 30 work days.
The Pilot Plan for Optimizing the Review and Approval Process of Clinical Trials with Innovative Drugs, which was announced in...